Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Int J Cancer. 2020 Jul 16;147(11):3160–3167. doi: 10.1002/ijc.33119

TABLE 3.

Daily TKI dose at the time of the first QTcf prolongation and the duration from TKI initiation and the development of the first QTcf prolongation for the following TKIs: Imatinib, Dasatinib, Sunitinib, Pazopanib and Nilotinib

Number ofTKI Daily TKI dose at the time Duration from TKI initiation and the first QTcf prolongation
Type ofTKI administrations that cause QTcf prolongation of the first QTcf prolongation <1 month 1–3 months 3–6 months 6 months-1 year >1 year
Imatinib 48 200 mg: 1 (2.1%)
300 mg: 2 (4.2%)
400 mg: 35 (72.9%)
500 mg: 1 (2.1%)
600 mg: 6 (12.5%)
800 mg: 3 (6.3%)		 10 (20.8%) 16 (33.3%) 15 (31.3%) 3 (6.3%) 4 (8.3%)
Pazopanib 32 200 mg: 2 (6.3%)
400 mg: 7 (21.9%)
600 mg 10 (31.3%)
800 mg: 13 (40.6%)		 6 (18.8%) 12 (37.5%) 10 (31.3%) 2 (6.3%) 2 (6.3%)
Sunitinib 26 25 mg: 3 (11.5%)
37.5 mg: 8 (30.8%)
50 mg: 15 (57.7%)		 5 (19.2%) 9 (34.6%) 11 (42.3%) 0 (0%) 1 (3.9%)
Dasatinib 48 20 mg: 3 (6.3%)
50 mg: 6 (12.5%)
70 mg: 8 (16.7%)
100 mg: 20 (41.2%)
140 mg: 11 (22.9%)		 10 (20.8%) 16 (33.3%) 17 (35.4%) 3 (6.3%) 2 (4.2%)
Nilotinib 29 300 mg: 2 (6.9%)
400 mg: 3 (10.3%)
600 mg: 5 (17.2%)
800 mg: 19 (65.5%)		 7 (24.1%) 10 (34.5%) 7 (24.1%) 3 (10.3%) 2 (6.9%)
Total 183 38 (20.8%) 63 (34.4%) 60 (32.8%) 11(6.0%) 10 (5.5%)